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ABSTRACT 
 
Background: Cystic fibrosis (CF) negatively impacts upon health-related quality of life (HRQoL) 
and survival. Adherence to nebulised treatments is low; improving adherence is hypothesised to 
reduce rates of exacerbation requiring intravenous antibiotics and lung function decline. 
Methods: A state transition model was developed to assess the cost-effectiveness of an intervention 
aimed at increasing patient adherence to nebulised and inhaled antibiotics compared with current CF 
care, in advance of the forthcoming CFHealthHub randomised controlled trial (RCT). The model 
estimates the costs and health outcomes for each option from the perspective of the UK National 
Health Service (NHS) and Personal Social Services (PSS) over a lifetime horizon. Health gains are 
valued in terms of quality-adjusted life years (QALYs) gained. Forced Expiratory Volume in 1 
Second (FEV1) trajectories are predicted over three lung function strata: (i) FEV1 LL)(91 40-
69%, and; (iii) FEV1 <40%. Additional states are included to represent post-lung transplantation and 
dead. The model was populated using CF Registry data, literature and expert opinion. Costs were 
valued at 2016 prices. Uncertainty was assessed using deterministic and probabilistic sensitivity 
analyses.  
Results: If effective, the adherence intervention is expected to produce an additional 0.19 QALYs and 
cost savings of £64,078 per patient. Across all analyses, the intervention dominated current care. Over 
a 5-year period, the intervention is expected to generate cost savings of £49.5million for the estimated 
2,979 CF patients with Pseudomonas aeruginosa currently aged 16 or above in the UK. If applied to a 
broader population of adult CF patients receiving any nebulised therapy, the expected savings could 
be considerably greater. 
Conclusions: If effective, the adherence intervention is expected to produce additional health gains at 
a lower cost than current CF care. The economic analysis should however be revisited upon 
completion of the full RCT. More generally, the analysis suggests that considerable gains could be 
accrued through the implementation of adherence interventions which shift care from expensive 
hospital-based rescue to community-based prevention. 
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KEY POINTS FOR DECISION-MAKERS 
x Based on a pre-trial analysis of the CFHealthHub study, the use of an effective adherence 
intervention for CF is expected to produce an additional 0.19 QALYs and cost savings of 
£64,078 per patient compared with current CF care. Over a 5-year period, this corresponds to 
cost savings of approximately £49.5million for the estimated 2,979 CF patients with 
Pseudomonas aeruginosa currently aged 16 or above in the UK.  
x If the adherence intervention benefits a broader population of CF patients who are receiving 
nebulised antibiotics and/or mucolytics and are aged 16 or over (likely to represent 
approximately 5,800 patients), the 5-year cost savings to the NHS are expected to be in excess of 
£96million. Given existing uncertainty, it will be important to revisit this economic analysis upon 
completion of the full CFHealthHub RCT. 
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1. INTRODUCTION 
Cystic fibrosis (CF) is an inherited condition characterised by the abnormal transport of chloride ions 
(Cl-) across transporting epithelia. This leads to the production of thick sticky mucus in the lungs, 
pancreas, liver, intestine, and reproductive tract, and an increase in the salt content in sweat. More 
than 10,000 children and adults in the UK have CF [1]. Whilst CF limits life expectancy, survival is 
increasing, and in 2015, approximately 6,475 CF sufferers in the UK were older than 16 years of age 
[1]. Amongst other problems, for example poor digestion, patients with CF are susceptible to lung 
infections, in particular, Pseudomonas aeruginosa. This is thought to be because the thick mucus 
makes it difficult for the body to clear inhaled bacteria, and because people with CF have an increased 
airway inflammatory response to pathogens [2]. People with CF often develop intermittent infections 
during childhood, which can be treated and even eradicated with nebulised or inhaled antibiotics. As 
infection develops, however, patients may reach a chronic stage whereby eradication is no longer 
possible due to the formation of biofilms [3]. In such cases, ongoing inhaled antibiotic treatment must 
be continued permanently. Patients commonly also require other treatments including inhaled 
mucolytics, bronchodilators, steroids, and physiotherapy [1]. Treatment is time consuming and 
burdensome [4], with administration of nebulised antibiotics taking up to an hour per day whilst 
patients are well and longer during periods of ill health. In addition, patients also experience 
pulmonary exacerbations which require treatment with intravenous (i.v.) antibiotics which are 
administered either DW KRPH RU LQ KRVSLWDO ,Q HLWKHU FDVH WKLV WUHDWPHQW FRPSURPLVHV WKH SDWLHQW¶V
ability to attend school or work and leads to increased health care costs. 
 
Adherence to preventative nebulised CF treatments is estimated at 48%, based on medication 
possession ratio (MPR) data in 3,287 people with CF aged 6 years and above in the US [5]. This is a 
measure of persistent adherence as these are chronic medications which are taken long-term [6]. 
These data show that adherence is inversely related to age. Importantly, MPR measures only 
medication that is collected from the pharmacy and cannot measure whether that medication is ever 
taken. Objective UK data using chipped nebulisers in adults goes beyond the coarse MPR adherence 
metric to determine objectively how much treatment is actually taken. These data suggest a lower 
median adherence rate of 36% in nebulisers that are brought to clinic to be downloaded [7]. It is also 
important to ensure that estimated adherence rates take into account the patienW¶V FOLQLFDO VWDWXV 
(³normative adherence´) and includes both nebulisers brought to clinic and the more difficult to 
obtain nebulisers left at home; UK data reported by Hoo et al suggest that when all nebulised devices 
are included, normative adherence in adult clinics may be as low as 33% [8]. 
 
Treatments only work if they are taken, and estimates of drug effectiveness are usually derived from 
randomised controlled trials (RCTs) whereby strict inclusion criteria and trial procedures typically 
produce high adherence rates. A recent review of adherence to CF treatments within clinical trials by 
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Pugatsch et al [9] reported an adherence rate of 80% as an aggregate estimate across the population 
over the entire duration of the studies (mean duration 7.3 months; range 2-24 months). The 
methodology for adherence measurement varied between trials, but was typically undertaken at 
frequent intervals across the trials and can be considered as a measure of persistent adherence [6]. 
Although there was a tendency for some reduction over time, adherence remained high across all 
phases of follow-up. Based on MPR data, it has been shown that CF patients with poor adherence 
(MPR <50%) have significantly higher healthcare costs than patients with good adherence 
(MPR>80%); most of the excess costs in poor adherers are related to hospital admission for i.v. rescue 
therapy to treat pulmonary exacerbations [5]. A meta-analysis reported by Demonceau et al assessed 
feedback of objective adherence data in various conditions across 5,237 patients; this study 
demonstrated that such feedback could increase adherence by around 20%, with a further 8% 
improvement if simple problem solving was added [10]. 
 
 The ongoing CFHealthHub ACtiF trial (Adherence to treatment in adults with Cystic Fibrosis) is 
currently assessing an intervention to improve outcomes for CF patients by empowering self-
management and improving adherence to nebulised therapy via the use of chipped nebulisers which 
have the capacity to directly monitor adherence levels, combined with an intervention to support 
problem solving, habit formation and self-efficacy undertaken by a member of the multidisciplinary 
team at regular appointments [11]. The hypothesis underpinning this RCT is that increasing adherence 
will reduce the number of exacerbations experienced by CF patients. Reducing the number of 
exacerbations experienced by CF patients may also impact on their rate of lung function deterioration.  
 
This paper presents an early health economic evaluation of the expected cost-effectiveness of the 
adherence intervention compared with current clinical care, in advance of the completion of the full 
CFHealthHub ACtiF RCT (due to complete in September 2019). More generally, this analysis 
provides a formal quantification of the potential gains which could be accrued by improving disease 
control in CF through improved adherence. 
 
2. METHODS 
2.1 Scope of the analysis 
A model-based cost-utility analysis was undertaken to assess the incremental cost-effectiveness of the 
adherence intervention versus standard care in adult CF patients receiving traditional nebulised or dry 
powder inhaled (DPI) antibiotics from the perspective of the National Health Service (NHS) and 
Personal Social Services (PSS) over a lifetime horizon. The intervention relates to a newly-developed 
nebuliser with the capacity to monitor and report adherence levels (developed as part of the 
CFHealthHub ACtiF programme [11]), combined with a behavioural intervention undertaken by a 
physiotherapist at regular appointments. Health benefits are assessed in terms of quality-adjusted life 
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years (QALYs) gained. All costs and health outcomes were discounted at a rate of 3.5% per annum 
[12]. Costs were valued at 2016 prices. 
 
2.2 Model structure 
The analysis uses a state transition approach, based on the structure of a previously published health 
economic model developed to assess the cost-effectiveness of DPIs for CF patients with chronic 
Pseudomonas aeruginosa [13;14]. The model was populated using analyses of individual patient data 
(IPD) from the UK CF Registry [15], literature and expert opinion. The model estimates Forced 
Expiratory Volume in 1 Second (FEV1) percent predicted trajectories over three strata of lung 
function: (1) FEV1 ; (2) FEV1 40-69%, and; (3) FEV1 <40% (Figure 1). Additional health states 
are included to represent post-lung transplantation and dead. During each annual cycle, patients may 
remain in their current FEV1 state, transit to an improved or worsened FEV1 state or die. A small 
proportion of patients with FEV1<40% may undergo lung transplantation and do not subsequently 
receive further nebulised/DPI treatment. HRQoL is modelled according to FEV1 stratum and 
transplant history, with disutilities applied according to the proportion of time spent receiving i.v. 
antibiotics to manage CF exacerbations. A half-cycle correction is applied to account for the timing of 
events. Total QALYs are calculated as the total sojourn time in each health state weighted by state-
specific utility scores, less any QALY losses resulting from exacerbations. The model conservatively 
assumes that there is no survival difference between the intervention and comparator groups. Costs 
include UK CF tariff treatment costs, high-cost drug acquisition, costs of i.v. days spent in hospital 
and associated i.v. antibiotic acquisition, transplantation costs and costs associated with the adherence 
intervention. All other costs are assumed to be captured in the CF banding tariff [16]. 
 
The model employs the following assumptions: 
x Patients in any FEV1 stratum can progress/regress to any other FEV1 stratum  
x Reductions in exacerbations impact upon progression rates between FEV1 strata 
x The probability of experiencing exacerbations differs by FEV1 stratum 
x A small proportion of patients with FEV1 <40% undergo lung transplant, whilst those 
ineligible for transplant continue to receive nebulised/DPI therapy 
x Reductions in lung function and the incidence of exacerbations impact upon HRQoL 
x The adherence intervention will impact upon the incidence of exacerbations and FEV1 
transitions  
x Exacerbation rates and transition rates between FEV1 strata are time-invariant  
x 7KHFRVWVRI³KLJK-cost therapies´ are independent of adherence to those therapies. 
 
Figure 1: Model structure 
[INSERT FIGURE 1 HERE] 
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2.3 Evidence used to inform the model parameters 
Model parameters and their associated distributional properties are summarised in Table 1.  
 
Table 1: Summary of model parameters 
[INSERT TABLE 1 HERE] 
 
Patient characteristics 
The population is assumed to be 16 years of age at model entry. The initial distribution of patients 
across the health states was based on recorded FEV1 in 2013 from the CF Registry (the most recent 
year available for the analysis). 
 
Transition probabilities 
Transition probabilities were derived from IPD from the CF Registry for a total of 10,344 patients 
between 2007 and 2013 [15]. The overall dataset was restricted to those patients who have been 
UHFRUGHG DW OHDVW RQFH DV KDYLQJ µLQWHUPLWWHQW¶ RU µFKURQLF¶ Pseudomonas aeruginosa status 
(n=7,518). Fifty-three percent of these patients were male, and their average age on first appearing in 
the 2007-2013 dataset was 19 years (range 0-82 years). At baseline, the proportion of patients in each 
FEV1 stratum was as follows: FEV1<40%=0.13; FEV1 40-69%=0.32; FEV1>70%=0.55. Of these, 
6,788 had at least one recorded FEV1 assessment and 1,700 had measures for all seven years. 
Longitudinal regression was undertaken using the methods described by Jung et al [23]; this involved 
the estimation of a series of ordered logit models which give the log odds of being in a given FEV1 
group post-transition, given the time (in days) between observations, the annual rate of hospital i.v. 
GD\VDQGWKHSDWLHQW¶VDJH2QHPRGHOwas estimated for each of three possible FEV1 starting states 
and the model outputs were converted into annual probabilities. This approach allowed for the 
inclusion of patients who had between 2 and 7 entries in the registry, even if there were gaps before, 
between, or after review entries. Patients who left the registry were excluded from the analysis. The 
time variable (days since last visit) allows for the calculation of annual transitions despite the fact that 
sample intervals varied in the raw registry data. The lagged rate of i.v. days variable allowed for the 
investigation of the effect of exacerbations on FEV1 progression. A number of models were tested 
with both age and sex as covariates. Age was statistically significant in most models, but sex was not 
significant, therefore age was retained in the final model.  
 
Mean days on i.v. antibiotics per year 
Mean days in hospital or at home receiving i.v. antibiotics for each FEV1 group were estimated from 
the same group of patients with Pseudomonas aeruginosa in the CF Registry used to derive transition 
probabilities [15].  
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Effectiveness of the adherence intervention  
The intervention is assumed to reduce the number of days on i.v. antibiotics, leading to changes in the 
transition rates between the FEV1 strata. The CFHealthHub ACtiF trial is powered to detect a 
reduction of one exacerbation per annum, based on a previous trial of long-term inhaled hypertonic 
saline for CF (Elkins et al [17]); this treatment effect is assumed to reflect the minimum clinically 
important difference. Assuming one exacerbation is equivalent to 14 days of home or hospital i.v. 
antibiotics [24;25], when applied to the whole CF Registry cohort with Pseudomonas aeruginosa, this 
equates to a 55% reduction in days spent receiving i.v. antibiotics. Uncertainty surrounding the 
relative risk reduction in i.v. days was assumed to broadly reflect that observed in the Elkins et al trial 
[17], but the 95% confidence interval [CI] was widened to account for additional uncertainty 
surrounding the effectiveness of the adherence intervention (mean relative risk=0.45, standard 
error=0.09). Post-intervention exacerbation rates were also applied to the logit models to derive FEV1 
transition probabilities for the adherence intervention. 
 
CF mortality 
The CF Registry does not include sufficient data to allow for the robust derivation of estimates of 
long-term survival for CF patients [15]. Instead, survival estimates were based on an analysis reported 
by Dodge et al [20]. This study reported survival data up to the end of 2003 for all subjects with CF 
born in the UK in the period 1968-1992 collated via active enquiry of CF clinics and other hospital 
consultants. The published survival curves for males and females were digitised and patient-level 
time-to-event data were reconstructed using methods reported by Guyot et al [26]. Parametric 
survivor functions (exponential, log normal, log logistic, Weibull, Gompertz and generalised gamma) 
were fitted to the replicated data to extrapolate beyond the observed follow-up period. Model 
discrimination was undertaken using visual inspection, an examination of the goodness-of-fit statistics 
for each survivor function (the Akaike Information criterion [AIC] and the Bayesian Information 
Criterion [BIC]), together with subjective clinical judgement regarding the plausibility of the 
extrapolated portion of each parametric curve. On the basis of clinical plausibility, the Gompertz 
survivor function was selected for use in the model. Uncertainty surrounding the parameters of the 
survivor function was modelled using independent normal distributions with the 95% CI width 
calibrated such that it was similar to that observed for patients in the current CF Registry population. 
The same function was applied to the intervention and comparator groups, hence the adherence 
intervention is not assumed to impact on patient survival. 
 
Probability of transplantation 
The probability that a patient with FEV1 <40% will undergo a lung transplant during each cycle was 
estimated based on data from the UK CF Registry [1] and the US Cystic Fibrosis Foundation, 
assuming a 2-3% lifetime probability of undergoing lung transplantation [13;14]. 
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HRQoL  
The selection of studies used to inform HRQoL parameters within the model was based on a previous 
systematic review [9]. Health state utilities associated with each FEV1 stratum and the disutility 
associated with exacerbations were based on a UK utility valuation study reported by Bradley et al 
[18]; within this study, the 3-level Euroqol-5 Dimensions (EQ-5D) and the Cystic Fibrosis 
Questionnaire-Revised (CFQ-5ZHUHDGPLQLVWHUHG WRSDWLHQWVDJHG\HDUVZLWK&) and chronic 
Pseudomonas aeruginosa and who were taking nebulised or oral antibiotics. The utility score for 
patients who have undergone lung transplantation was taken from a cross sectional utility valuation 
study involving 3-level EQ-5D assessments in patients awaiting lung transplantation and transplant 
recipients attending follow up clinics in the UK [19].  
 
Resource costs 
The model includes costs associated with CF tariff banding, high cost antibiotic therapies, hospital i.v. 
days, i.v. antibiotics, transplantation and the adherence intervention. The proportion of patients in 
each band of the CF tariff according to FEV1 stratum were derived from the CF Registry [15]; 
banding tariff costs were taken from the latest NHS National Tariff [16]. Usage of specific antibiotic 
products was estimated from the CF Registry dataset [15]. The analysis assumes that patients are 
prescribed these treatments according to their licensed dosing schedules rather than according to 
patient adherence levels. Unit costs for nebulised and DPI antibiotics were derived from British 
National Formulary (BNF) 2016 [21]. Transplantation costs were based on personal communication 
(Kim Cox, NHS England). The costs of i.v. antibiotics (tobramycin and ceftazidime) were sourced 
from Sheffield Teaching Hospitals (personal communication: Tim Gleeson, Sheffield Teaching 
Hospitals, England, 2016). The cost of a hospital i.v. day was based on NHS Reference Costs 
2014/15; as there is no inpatient cost relating to CF exacerbations, the daily cost associated with a 
long stay inpatient admission for bronchiectasis with complications and comorbidity score 0 was 
assumed (daily cost = £361.68) [22]. The model assumes that 54% i.v. days take place in hospital; the 
UHPDLQLQJDUHDVVXPHGWRWDNHSODFHDWWKHSDWLHQW¶VKRPHDQGGRnot lead to additional costs for 
the NHS (personal communication: Tim Gleeson, Sheffield Teaching Hospitals, England, 2016). The 
costs of the adherence intervention were assumed to include a once-only cost for data transfer 
hardware of £121.20 plus an ongoing annual data transfer cost of £583.44 per patient (personal 
communication: Martin Wildman, Sheffield Teaching Hospitals, England, 2016). The analysis 
assumes that the training and implementation costs associated with the behavioural impact component 
of the adherence intervention would be absorbed into routine clinic appointments undertaken by CF 
healthcare practitioners and therefore these costs have been excluded. 
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Model evaluation methods 
Cost-effectiveness was expressed in terms of the incremental cost per QALY gained. Uncertainty 
surrounding the cost-effectiveness of the adherence intervention was explored using deterministic 
sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA). The PSA included all 
uncertain model parameters and was implemented using simple Monte Carlo sampling methods 
(2,000 random iterations). DSAs were conducted to explore the impact of alternative time horizons, 
assumptions of a less durable treatment effect, an assumption that the intervention impacts on 
exacerbation rates only, reduced impacts on exacerbation rates, and alternative assumptions regarding 
cost and utility parameters. In addition, a further scenario was conducted whereby treatment costs 
were calculated according to expected adherence levels in each group, based on Daniels et al [7] (36% 
drug consumption in current CF care group) and Demonceau et al [10] (63.7% drug consumption for 
the adherence intervention group). 
 
Model validation methods 
Several measures were taken to verify the implemented model and to the ensure the credibility of its 
underlying conceptual basis. These included internal peer review by clinical experts, scrutiny of the 
implemented model coding and formulae, checking the accuracy of all model inputs against sources, 
investigating potentially discrepant or unexpected results identified through black box testing and 
double-programming of the deterministic model. Whilst the results of the CFHealthHub ACtiF trial 
will not be available until at least September 2019, once available, this evidence will allow the 
economic analysis to be updated using prospectively collected randomised data; this will also enable 
the comparison of the predictions of the pre-trial and post-trial analyses. 
 
3. RESULTS 
3.1 Central estimates of cost-effectiveness 
Table 2 presents the central estimates of cost-effectiveness for the adherence intervention versus 
current CF care based on the probabilistic version of the model. 
 
Table 2: Central estimates of cost-effectiveness (probabilistic)  
[INSERT TABLE 2 HERE] 
 
The probabilistic version of the model suggests that, if effective, the adherence intervention is 
expected to produce an additional 0.19 discounted QALYs per patient and cost-savings of 
approximately £64,078 per patient over their remaining lifetime; hence, the adherence intervention is 
expected to dominate current care. The cost savings predicted by the model are driven by a small shift 
in CF banding resulting from improvements in predicted FEV1 trajectory, together with a significant 
reduction in the expected number of hospital i.v. days (accounting for savings of approximately 
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£70,000 per patient). As shown in the cost-effectiveness plane (Figure 2), whilst there is considerable 
uncertainty surrounding the health gains associated with the intervention, the probabilistic analysis 
consistently indicates that the adherence intervention is expected to produce substantial cost savings. 
Across willingness-to-pay thresholds of between £0 and £100,000 per QALY gained, the probability 
that the adherence intervention produces more net benefit than current care is expected to be 1.0.  
 
3.2 Sensitivity analysis results 
Across all of the DSAs, the adherence intervention is expected to dominate current care (Table 3). 
This includes the highly pessimistic situation whereby the costs of high cost drugs calculated exactly 
according to the level patient adherence, based on Daniels et al [7] and Demonceau et al [10]. Even in 
this unlikely scenario, the savings associated with costs of i.v. hospital days avoided outweigh the 
additional costs of drug therapy due to increased patient adherence to nebulised and inhaled therapy. 
Assuming that treatment costs are independent of adherence levels, the sensitivity analysis suggests 
that over the course of 5-years, the model estimates discounted cost savings of £16,623 per patient; 
this is equivalent to approximately £49.5million for the estimated 2,979 CF patients with 
Pseudomonas aeruginosa currently aged 16 or above in the UK. Should the intervention benefit a 
broader population of CF patients who are receiving nebulised antibiotics and/or mucolytics and are 
aged 16 or over (likely to represent approximately 5,800 patients), the 5-year cost savings to the NHS 
are expected to be in excess of £96million. 
 
Table 3: Deterministic sensitivity analysis results 
[INSERT TABLE 3 HERE] 
 
Figure 2: Cost-effectiveness plane 
[INSERT TABLE 3 HERE] 
 
4. DISCUSSION 
This study represents the first health economic analysis of an intervention targeted at increasing 
patient adherence to nebulised/DPI treatments in CF. The results of the analysis suggest that the 
adherence intervention has the potential to produce considerable health gains as well as cost savings 
for the NHS, thereby dominating current CF care. The principal driver of the anticipated cost savings 
is due to the expected reduction in hospital i.v. days. The sensitivity analysis suggests that even under 
pessimistic assumptions regarding lower levels of effectiveness of the intervention and lower unit 
costs per i.v. day, the adherence intervention is expected to remain dominant. This suggests that even 
if the CFHealthHub ACtiF trial does not meet its primary endpoint, the intervention may still produce 
cost savings for the health service. 
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Since this health economic analysis precedes the CFHealthHub ACtiF trial, there is considerable 
uncertainty regarding whether the findings of the analysis will concord with the data that will be 
collected within the trial itself. Invariably, such early modelling analyses are subject to the risk of 
reaching erroneous conclusions and rely on a weaker evidence base than would be available had the 
full trial been completed. It is therefore important to consider these evidential issues in the 
interpretation of the results of this analysis; these limitations are discussed briefly below. 
 
(i) Clinical evidence to support the effectiveness of the adherence intervention 
The most pertinent limitation of the evidence base is that the CFHealthHub ACtiF trial, which aims to 
assess the clinical benefit of the adherence intervention, has not yet begun. As such, there is currently 
no direct empirical evidence through which to quantify the benefits of the adherence intervention. 
Given this lack of evidence, the model uses the expected reduction in exacerbations used to inform the 
power calculations for the CFHealthHub ACtiF trial [11;17] as the basis for modelling expected 
treatment effects. Whilst this estimate reflects a legitimate prior belief, and forms the basis of the 
hypothesis that will be tested within the trial, there is a possibility that the anticipated reduction in 
exacerbations could be higher or lower than predicted. Nonetheless, the economic analysis presented 
here has a wider relevance in quantifying the potential gains that could be accrued through the 
implementation of adherence interventions which shift care from expensive hospital-based rescue to 
more economical community-based prevention. This analysis may therefore be useful in supporting 
the development and evaluation of other adherence interventions within the NHS or across other 
health care systems.  
 
(ii) Transition probabilities and exacerbation rates are assumed to apply indefinitely 
The model uses a single matrix of probabilities describing the trajectories of lung function across 
three FEV1 strata in each treatment group. Whilst age is included as a covariate in the logit regression 
analyses, these are treated as time-independent parameters within the health economic model. In 
reality, FEV1 transitions may be time-variant. Owing to the absence of long-term data on FEV1 
trajectories with and without the intervention, the model assumes that these trajectories remain 
constant with respect to time. It should be noted however, that the economic conclusions drawn from 
the analysis remain unchanged even if the intervention has no impact upon lung function decline 
(Table 3).  
 
(iii) Treatment effect assumed to apply indefinitely 
Given the preliminary nature of the health economic analysis and the current lack of evidence 
regarding the effectiveness of the adherence intervention, the model assumes that the treatment effect 
applies LQGHILQLWHO\RYHUWKHSDWLHQW¶VUHPDLQLQJOLIHWLPH It may be the case that levels of adherence to 
antibiotic therapies may increase or wane over time following the introduction of the intervention. 
13 
 
The sensitivity analysis suggests that both health gains and cost savings are expected to be reduced 
over shorter intervals, although the intervention is expected to remain dominant irrespective of the 
time horizon and assumptions regarding the durability of the treatment effect. 
 
(iv) Limitations in handling cost savings due to the CF banding tariff 
Within the model, benefits and costs are captured through two different processes: (i) a direct 
reduction in the number of days spent receiving i.v. antibiotics, and; (ii) the impact of reduced 
exacerbations on subsequent FEV1 trajectory. In England, CF care is currently funded via a mandatory 
tariff for specialist commissioning which is intended to reflect the severity of disease in individual 
patients; the UK CF banding tariff is intended to encapsulate both lung function and i.v. days. 
Consequently, an analysis which accounts only for changes in the CF tariff band would fail to fully 
reflect cost savings realised by the NHS due to fewer i.v. days spent in hospital; this would lead to an 
underestimate of the true cost-effectiveness of the adherence intervention. Alternatively, an analysis 
which includes CF banding costs as well as i.v. hospital costs, as has been assumed here, may 
overestimate the cost-savings associated with reducing exacerbations. It is anticipated that the data 
collection mechanisms within the CFHealthHub ACtiF trial will allow for a more sensitive and 
accurate analysis of the true costs associated with the adherence intervention based on the direct 
modelling of FEV1 status and CF banding categories. 
 
(v) Relationship between treatment costs and patient adherence  
There is uncertainty regarding the relationship between the costs of treatment and patient adherence to 
those treatments. The base case analysis assumes that antibiotic treatment costs borne by the NHS are 
independent of patient adherence levels. It is possible that increasing adherence levels will also lead to 
increases in total NHS expenditure on antibiotic treatments: as patients become more adherent to 
therapy, they may require more frequent prescriptions. The consequence of this situation would be an 
increase in the total CF drugs bill, and the expected cost savings of increased adherence would be 
somewhat diminished. However, the sensitivity analyses indicate that even in the presence of very 
pessimistic assumptions regarding the relationship between treatment adherence and treatment costs, 
specifically a scenario whereby treatment costs borne by the NHS exactly reflect patient consumption 
of those treatments, the adherence intervention is expected to remain cost-saving (Table 3). 
 
5. CONCLUSIONS 
Based on an early health economic analysis using high quality registry data [1;15] and the estimated 
reduction in exacerbations used to inform the design of the CFHealthHub ACtiF trial [11], the 
adherence intervention is expected to produce additional health gains at a substantially lower cost than 
current CF care. The findings of the analysis should be revisited upon the completion of the full RCT. 
More broadly, the analysis suggests that considerable gains could be accrued through the 
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implementation of adherence interventions which shift care from hospital-based rescue to community-
based prevention.  
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Figure 1: Model structure 
 
 
 
 
 
Figure 2: Cost-effectiveness plane 
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Table 1: Model parameters 
Parameter Distribution Parameter 1 Parameter  2 Mean Source 
General parameters 
Time horizon (years) n/a - - 84 n/a 
Cycle length (years) n/a - - 1 n/a 
Start age (years) n/a - - 16 Assumption 
Discount rate QALYs n/a - - 3.50% NICE Methods Guide [12] 
Discount rate costs n/a - - 3.50% 
Initial distribution 
FEV1  Dirichlet 2891.00 5715.00 0.51 CF Registry dataset [15] 
FEV1 40%-60% Dirichlet 1965.00 5715.00 0.34 
FEV1 <40% Dirichlet 859.00 5715.00 0.15 
Post-transplant - - - 0 Assumption 
Dead - - - 0 
Transition probabilities ± current clinical care 
FEV1 WR)(91  Dirichlet 6056.33 6999.00 0.87 Logit model fitted to CF Registry dataset [15] 
FEV1 WR)(91 40%-60% Dirichlet 920.69 6999.00 0.13 
FEV1 WR)(91 <40% Dirichlet 21.98 6999.00 0.00 
FEV1 40%-60% to FEV1  Dirichlet 502.08 3743.00 0.13 
FEV1 40%-60% to FEV1 40%-60% Dirichlet 2860.77 3743.00 0.76 
FEV1 40%-60% to FEV1 <40% Dirichlet 380.15 3743.00 0.10 
FEV1 <40% to FEV1  Dirichlet 35.37 1350.00 0.03 
FEV1 <40% to FEV1 40%-60% Dirichlet 185.16 1350.00 0.14 
FEV1 <40% to FEV1 <40% Dirichlet 1129.47 1350.00 0.84 
Transition probabilities ± post-intervention 
FEV1 WR)(91  Dirichlet 6100.83 6999.00 0.87 Logit model fitted to CF Registry data [15] 
including ACtiF trial power calculation [11] FEV1 WR)(91 40%-60% Dirichlet 877.38 6999.00 0.13 
FEV1 WR)(91 <40% Dirichlet 20.79 6999.00 0.00 
FEV1 40%-60% to FEV1  Dirichlet 545.51 3743.00 0.15 
FEV1 40%-60% to FEV1 40%-60% Dirichlet 2849.04 3743.00 0.76 
FEV1 40%-60% to FEV1 <40% Dirichlet 348.45 3743.00 0.09 
FEV1 <40% to FEV1  Dirichlet 34.65 1350.00 0.03 
FEV1 <40% to FEV1 40%-60% Dirichlet 182.04 1350.00 0.13 
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Parameter Distribution Parameter 1 Parameter  2 Mean Source 
FEV1 <40% to FEV1 <40% Dirichlet 1133.30 1350.00 0.84 
Transplant rate 
Probability transplant/year (FEV1 <40%) Normal 0.004 0.000 0.004 Based on CF Registry [1] and US CF Foundation 
i.v. days (exacerbations) ± baseline 
i.v. days - FEV1  Beta 1802.23 42817.94 0.04 Observed data from CF registry dataset [15] 
i.v. days - FEV1 40%-60% Beta 3134.66 32608.88 0.09 
i.v. days - FEV1 <40% Beta 1184.13 6181.86 0.16 
i.v. days (exacerbations) ± post-intervention 
Relative risk of exacerbation requiring 
i.v. treatment  
Log normal 0.45 0.09 0.45 Power calculation based on Elkins et al [17]. 
Additional uncertainty included in 95% CI. 
i.v. days - FEV1  N/a - 0.02 - Calculated using baseline i.v. days and relative 
risk of exacerbation requiring i.v. treatment  i.v. days - FEV1 40%-60% N/a - 0.04 - 
i.v. days - FEV1 <40% N/a - 0.07 - 
Health-related quality of life 
Utility FEV1  Beta 108.52 17.08 0.86 Bradley et al [18] 
Disutility FEV1 WR)(91 40-69% Beta 4.11 72.01 0.05 
Disutility FEV1 40%-69% to FEV1 
<40% Beta 12.60 61.51 0.17 
Disutility i.v. exacerbation Beta 3.48 16.53 0.17 
Utility - post-transplant Beta 319.31 65.40 0.83 Anyanwu et al [19] 
Survival  
Gompertz - constant Normal 0.004 0.00 0.00 Parametric survivor function fitted to data 
reported by Dodge et al [20] 
Gompertz - gamma Normal 0.06 0.01 0.06  
CF banding by FEV1% 
FEV1 - Proportion band 1 Dirichlet 886 4418.00 0.20 CF Registry dataset [15] 
FEV1 - Proportion band 1a Dirichlet 83.00 4418.00 0.02 
FEV1 - Proportion band 2 Dirichlet 1063.00 4418.00 0.24 
FEV1 - Proportion band 2a Dirichlet 1497.00 4418.00 0.34 
FEV1 - Proportion band 3 Dirichlet 799.00 4418.00 0.18 
FEV1 - Proportion band 4 Dirichlet 75.00 4418.00 0.02 
FEV1 - Proportion band 5 Dirichlet 15.00 4418.00 0.00 
FEV1 40%-60% - Proportion band 1 Dirichlet 115.00 2290.00 0.05 
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Parameter Distribution Parameter 1 Parameter  2 Mean Source 
FEV1 40%-60% - Proportion band 1a Dirichlet 28.00 2290.00 0.01 
FEV1 40%-60% - Proportion band 2 Dirichlet 250.00 2290.00 0.11 
FEV1 40%-60% - Proportion band 2a Dirichlet 807.00 2290.00 0.35 
FEV1 40%-60% - Proportion band 3 Dirichlet 787.00 2290.00 0.34 
FEV1 40%-60% - Proportion band 4 Dirichlet 247.00 2290.00 0.11 
FEV1 40%-60% - Proportion band 5 Dirichlet 56.00 2290.00 0.02 
FEV1 <40% - Proportion band 1 Dirichlet 20.00 947.00 0.02 
FEV1 <40% - Proportion band 1a Dirichlet 6.00 947.00 0.01 
FEV1 <40% - Proportion band 2 Dirichlet 60.00 947.00 0.06 
FEV1 <40% - Proportion band 2a Dirichlet 234.00 947.00 0.25 
FEV1 <40% - Proportion band 3 Dirichlet 310.00 947.00 0.33 
FEV1 <40% - Proportion band 4 Dirichlet 225.00 947.00 0.24 
FEV1 <40% - Proportion band 5 Dirichlet 92.00 947.00 0.10 
High cost drug use 
Dornase alpha Beta 3949.00 2660.00 0.60 CF Registry dataset [15] 
Tobramycin Beta 779.00 5830.00 0.12 
Aztreonam Beta 235.00 6374.00 0.04 
Colistimethate sodium (Colomycin) Beta 2555.00 4054.00 0.39 
Colistimethate sodium (Promixin) Beta 1602.00 5007.00 0.24 
Tobi+Podhaler Beta 779.00 5830.00 0.12 
CF banding costs 
Cost band 1 Fixed £5,033 - £5,033 NHS England Monitor report 2016 Annex A 
[16] Cost band 1a Fixed £7,447 - £7,447 
Cost band 2 Fixed £7,447 - £7,447 
Cost band 2a Fixed £12,036 - £12,036 
Cost band 3 Fixed £18,422 - £18,422 
Cost band 4 Fixed £33,224 - £33,224 
Cost band 5 Fixed £40,054 - £40,054 
Drug costs 
Dornase alpha Fixed £6,044.04 - £6,044.04 British National Formulary 2016 [21] 
Tobramycin Fixed £6,016.25 - £6,016.25 
Aztreonam Fixed £14,228.64 - £14,228.64 
Colistimethate sodium (Colomycin) Fixed £2,366.82 - £2,366.82 
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Parameter Distribution Parameter 1 Parameter  2 Mean Source 
Colistimethate sodium (Promixin) Fixed £8,181.60 - £8,181.60 
Tobi+Podhaler Fixed £11,674.96 - £11,674.96 
Adherence intervention - marginal costs 
Once-only data transfer hardware Fixed £121.20 - £121.20 Personal communication - Martin Wildman, 
Sheffield Teaching Hospitals, England, 2016 Annual data transfer Fixed £158.40 - £583.44 
Other costs  
Cost i.v. day Normal £361.68 £77.48 £361.68 NHS Reference Costs 2014/15 - Long stay 
bronchiectasis, CC score 0 [22] 
Proportion of i.v. days in hospital Beta 93,455.00 78,452.00 0.54 Personal communication - Tim Gleeson, 
Sheffield Teaching Hospitals, England, 2016 
Cost of i.v. ceftazidime and tobramycin 
per day 
Fixed £71.99 - £71.99 Personal communication - Martin Wildman, 
Sheffield Teaching Hospitals, England, 2015 
Cost transplant Normal £40,000.00 £4,000.00 £40,000.00 Personal communication - Kim Cox, NHS 
England, 2015 
Param ± parameter; n/a -  not applicable; QALY ± quality-adjusted life year; i.v. intravenous; FEV1 ± forced expiratory volume in 1 second; NICE ± National Institute for Health and Care 
Excellence; NHS ± National Health Service; CF ± cystic fibrosis; CC ± comorbidities and complications 
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Table 2: Central estimates of cost-effectiveness (probabilistic) 
Option QALYs Costs Incremental 
QALYs  
Incremental 
Costs 
Incremental cost 
per QALY gained 
Adherence intervention 12.24 £431,261 0.19 -£64,078 Dominating 
Current care 12.05 £495,338 - - - 
QALY ± quality-adjusted life year; ICER ± incremental cost-effectiveness ratio 
 
 
Table 3: Deterministic sensitivity analysis results 
Scenario Adherence intervention versus 
current care 
ICER  
Incremental 
QALYs 
Incremental 
costs 
Base case  0.19 £63,832 dominating 
Undiscounted results 0.34 £106,715 dominating 
5-year time horizon 0.04 £16,623 dominating  
10-year time horizon 0.08  £30,871 dominating  
20-year time horizon 0.15  £50,257 dominating  
Intervention impacts on i.v. days only 0.12  £59,314 dominating  
25% reduction in exacerbation rate RR (relative 
risk reduction=0.58) 
0.16  £47,213 dominating  
50% reduction in exacerbation rate RR (relative 
risk reduction=0.72) 
0.13 £30,594 dominating  
Cost i.v. days halved 0.19  £38,263 dominating 
Cost of adherence intervention doubled 0.19  £54,796 dominating 
i.v. disutility doubled 0.32  £63,832 dominating 
i.v. disutility halved 0.13  £63,832 dominating 
Treatment costs assumed to exactly reflect patient 
consumption based on Daniels et al [3] and 
Demonceau et al [6] 
0.19  £25,247 dominating 
i.v. ± intravenous; RR ± relative risk; QALY ± quality-adjusted life year; ICER ± incremental cost-effectiveness ratio 
 
 
 
